CA Patent

CA2680207A1 — Nanoparticle comprising rapamycin and albumin as anticancer agent

Assigned to Abraxis Bioscience LLC · Expires 2008-09-12 · 18y expired

What this patent protects

The present invention features methods for treating, stabilizing, prevent ing, and/or delaying cancer by administering nanoparticles that comprise rap amycin or a derivative thereof. The invention also provides compositions (e. g., unit dosage forms) comprising nanoparticles that…

USPTO Abstract

The present invention features methods for treating, stabilizing, prevent ing, and/or delaying cancer by administering nanoparticles that comprise rap amycin or a derivative thereof. The invention also provides compositions (e. g., unit dosage forms) comprising nanoparticles that comprise a carrier prot ein and rapamycin or a derivative thereof. The invention further provides co mbination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.

Drugs covered by this patent

Patent Metadata

Patent number
CA2680207A1
Jurisdiction
CA
Classification
—
Expires
2008-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.